Solitary Plasmacytoma Treated by Lenalidomide-Dexamethasone in Combination with Radiation Therapy: Clinical Outcomes
The study evaluates the results of the concurrent use of lenalidomide-dexamethasone with intensity modulated radiation therapy (IMRT) for solitary plasmacytoma in terms of toxicity and outcome. Forty-six patients were treated for histologically proven solitary plasmacytoma (SP) between June 2007 and...
Saved in:
| Published in | International journal of radiation oncology, biology, physics Vol. 106; no. 3; pp. 589 - 596 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.03.2020
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0360-3016 1879-355X 1879-355X |
| DOI | 10.1016/j.ijrobp.2019.10.043 |
Cover
| Abstract | The study evaluates the results of the concurrent use of lenalidomide-dexamethasone with intensity modulated radiation therapy (IMRT) for solitary plasmacytoma in terms of toxicity and outcome.
Forty-six patients were treated for histologically proven solitary plasmacytoma (SP) between June 2007 and June 2018 in our Department (Curie Institute, Paris, France). All patients received IMRT. The median total dose was 40 Gy (range, 40-46). Prescription of concurrent lenalidomide-dexamethasone with radiation therapy was left to the discretion of the referring hematologist-oncologist and started the first day of radiation therapy for 4 cycles.
Twenty-seven solitary plasmacytoma were treated with IMRT alone and 19 with lenalidomide-dexamethasone in association with IMRT. At 5 years, the local control, multiple myeloma–free survival (MMFS), and progression-free survival (PFS) rates were 96.3%, 85.4%, and 60%. MMFS and PFS were significantly higher in the IMRT plus lenalidomide-dexamethasone group compared with IMRT alone group (100% vs 77.1%, P = .02 and 81.7% vs 48.4%, P = .047, respectively). No major toxicity was found in either group.
Lenalidomide-dexamethasone in association with IMRT in the treatment of solitary plasmacytoma is safe and improves MMFS and PFS. Further prospective and comparative studies are needed to confirm these results. |
|---|---|
| AbstractList | The study evaluates the results of the concurrent use of lenalidomide-dexamethasone with intensity modulated radiation therapy (IMRT) for solitary plasmacytoma in terms of toxicity and outcome.
Forty-six patients were treated for histologically proven solitary plasmacytoma (SP) between June 2007 and June 2018 in our Department (Curie Institute, Paris, France). All patients received IMRT. The median total dose was 40 Gy (range, 40-46). Prescription of concurrent lenalidomide-dexamethasone with radiation therapy was left to the discretion of the referring hematologist-oncologist and started the first day of radiation therapy for 4 cycles.
Twenty-seven solitary plasmacytoma were treated with IMRT alone and 19 with lenalidomide-dexamethasone in association with IMRT. At 5 years, the local control, multiple myeloma-free survival (MMFS), and progression-free survival (PFS) rates were 96.3%, 85.4%, and 60%. MMFS and PFS were significantly higher in the IMRT plus lenalidomide-dexamethasone group compared with IMRT alone group (100% vs 77.1%, P = .02 and 81.7% vs 48.4%, P = .047, respectively). No major toxicity was found in either group.
Lenalidomide-dexamethasone in association with IMRT in the treatment of solitary plasmacytoma is safe and improves MMFS and PFS. Further prospective and comparative studies are needed to confirm these results. The study evaluates the results of the concurrent use of lenalidomide-dexamethasone with intensity modulated radiation therapy (IMRT) for solitary plasmacytoma in terms of toxicity and outcome.PURPOSEThe study evaluates the results of the concurrent use of lenalidomide-dexamethasone with intensity modulated radiation therapy (IMRT) for solitary plasmacytoma in terms of toxicity and outcome.Forty-six patients were treated for histologically proven solitary plasmacytoma (SP) between June 2007 and June 2018 in our Department (Curie Institute, Paris, France). All patients received IMRT. The median total dose was 40 Gy (range, 40-46). Prescription of concurrent lenalidomide-dexamethasone with radiation therapy was left to the discretion of the referring hematologist-oncologist and started the first day of radiation therapy for 4 cycles.METHODS AND MATERIALSForty-six patients were treated for histologically proven solitary plasmacytoma (SP) between June 2007 and June 2018 in our Department (Curie Institute, Paris, France). All patients received IMRT. The median total dose was 40 Gy (range, 40-46). Prescription of concurrent lenalidomide-dexamethasone with radiation therapy was left to the discretion of the referring hematologist-oncologist and started the first day of radiation therapy for 4 cycles.Twenty-seven solitary plasmacytoma were treated with IMRT alone and 19 with lenalidomide-dexamethasone in association with IMRT. At 5 years, the local control, multiple myeloma-free survival (MMFS), and progression-free survival (PFS) rates were 96.3%, 85.4%, and 60%. MMFS and PFS were significantly higher in the IMRT plus lenalidomide-dexamethasone group compared with IMRT alone group (100% vs 77.1%, P = .02 and 81.7% vs 48.4%, P = .047, respectively). No major toxicity was found in either group.RESULTSTwenty-seven solitary plasmacytoma were treated with IMRT alone and 19 with lenalidomide-dexamethasone in association with IMRT. At 5 years, the local control, multiple myeloma-free survival (MMFS), and progression-free survival (PFS) rates were 96.3%, 85.4%, and 60%. MMFS and PFS were significantly higher in the IMRT plus lenalidomide-dexamethasone group compared with IMRT alone group (100% vs 77.1%, P = .02 and 81.7% vs 48.4%, P = .047, respectively). No major toxicity was found in either group.Lenalidomide-dexamethasone in association with IMRT in the treatment of solitary plasmacytoma is safe and improves MMFS and PFS. Further prospective and comparative studies are needed to confirm these results.CONCLUSIONSLenalidomide-dexamethasone in association with IMRT in the treatment of solitary plasmacytoma is safe and improves MMFS and PFS. Further prospective and comparative studies are needed to confirm these results. Purpose: The study evaluates the results of the concurrent use of lenalidomide-dexamethasone with intensity modulated radiation therapy (IMRT) for solitary plasmacytoma in terms of toxicity and outcome. Methods and Materials: Forty-six patients were treated for histologically proven solitary plasmacytoma (SP) between June 2007 and June 2018 in our Department (Curie Institute, Paris, France). All patients received IMRT. The median total dose was 40 Gy (range, 40-46). Prescription of concurrent lenalidomide-dexamethasone with radiation therapy was left to the discretion of the referring hematologist-oncologist and started the first day of radiation therapy for 4 cycles. Results: Twenty-seven solitary plasmacytoma were treated with IMRT alone and 19 with lenalidomide-dexamethasone in association with IMRT. At 5 years, the local control, multiple myeloma–free survival (MMFS), and progression-free survival (PFS) rates were 96.3%, 85.4%, and 60%. MMFS and PFS were significantly higher in the IMRT plus lenalidomide-dexamethasone group compared with IMRT alone group (100% vs 77.1%, P = .02 and 81.7% vs 48.4%, P = .047, respectively). No major toxicity was found in either group. Conclusions: Lenalidomide-dexamethasone in association with IMRT in the treatment of solitary plasmacytoma is safe and improves MMFS and PFS. Further prospective and comparative studies are needed to confirm these results. |
| Author | Mignot, Fabien Bouscary, Didier Vignon, Marguerite Arsène-Henry, Alexandre Kirova, Youlia Schernberg, Antoine |
| Author_xml | – sequence: 1 givenname: Fabien surname: Mignot fullname: Mignot, Fabien email: fabien.mignot@curie.fr organization: Department of Radiation Oncology, Institut Curie, Paris, France – sequence: 2 givenname: Antoine surname: Schernberg fullname: Schernberg, Antoine organization: Department of Radiation Oncology, Institut Curie, Paris, France – sequence: 3 givenname: Alexandre surname: Arsène-Henry fullname: Arsène-Henry, Alexandre organization: Department of Radiation Oncology, Institut Curie, Paris, France – sequence: 4 givenname: Marguerite surname: Vignon fullname: Vignon, Marguerite organization: Department of Hematology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France – sequence: 5 givenname: Didier surname: Bouscary fullname: Bouscary, Didier organization: Department of Hematology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France – sequence: 6 givenname: Youlia surname: Kirova fullname: Kirova, Youlia organization: Department of Radiation Oncology, Institut Curie, Paris, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31707123$$D View this record in MEDLINE/PubMed https://hal.science/hal-03227875$$DView record in HAL |
| BookMark | eNqFkU1vEzEYhC1URNPCP0DIRzhseG1v9qNCSFUoFClSEQSJm-X1vqs4eNfBdgr77-toUw695GR59MzInrkgZ4MbkJDXDOYMWPF-Ozdb75rdnAOrkzSHXDwjM1aVdSYWi19nZAaigEwk-JxchLAFAMbK_AU5F6yEknExI_GHsyYqP9JvVoVe6TG6XtG1RxWxpc1IVzgoa1rXmxazT_hP9Rg3KqTHUDPQpesbM6ho3ED_mrih31Vrput6g17txiu6tGYwWll6t4_a9RhekuedsgFfHc9L8vPzzXp5m63uvnxdXq8yned1zETXsI53ORRQQlFXHbasZgXWoGoBRcsqqESea9bkFas7zYuiUm3FecNZ1UEjLsm7KXejrNx506d_SqeMvL1eyYMGgvOyKhf3LLFvJ3bn3Z89hih7EzRaqwZ0-yC5YKJYcKhFQt8c0X3TY_s_-bHVBFxNgPYuBI-d1KnjQynRK2MlA3mYUG7lNKE8THhQ04TJnD8xP-afsH2cbJgKvTfoZdAGB42t8aijbJ05FfDhSYA-7vYbx9P2B5Dxy7M |
| CitedBy_id | crossref_primary_10_1182_blood_2023021187 crossref_primary_10_7759_cureus_52460 crossref_primary_10_1016_j_rhum_2024_01_008 crossref_primary_10_3324_haematol_2022_282214 crossref_primary_10_1155_2022_7531142 crossref_primary_10_1002_cam4_3533 crossref_primary_10_1016_j_ijrobp_2019_12_029 crossref_primary_10_1002_cam4_7017 crossref_primary_10_1016_j_semradonc_2024_10_004 crossref_primary_10_3389_fpubh_2022_954816 crossref_primary_10_1080_10428194_2022_2118535 crossref_primary_10_3390_cancers12030676 crossref_primary_10_1016_j_radcr_2024_01_065 crossref_primary_10_1097_COC_0000000000000948 crossref_primary_10_7759_cureus_26502 crossref_primary_10_1097_CAD_0000000000001041 crossref_primary_10_4081_hr_2020_8396 crossref_primary_10_1016_j_clml_2022_07_003 crossref_primary_10_1016_j_ijrobp_2019_12_031 |
| Cites_doi | 10.1016/j.ijrobp.2005.06.039 10.1016/S0360-3016(00)01572-8 10.1002/cncr.26031 10.1080/10428194.2017.1393667 10.1371/journal.pone.0219857 10.1186/s12885-016-2824-x 10.1016/j.ijrobp.2010.11.037 10.1111/j.1365-2141.2008.07421.x 10.1186/s12885-016-3015-5 10.1186/1471-2407-6-118 10.1182/blood-2014-04-566521 10.1016/S1470-2045(14)70442-5 10.1182/blood.V128.22.4514.4514 10.1056/NEJMoa1402551 10.1016/0360-3016(89)90008-4 10.1016/j.meddos.2010.12.009 10.4329/wjr.v5.i6.248 10.1111/bjh.14291 10.1186/s13045-017-0549-1 10.1002/(SICI)1099-1069(199609)14:3<111::AID-HON575>3.0.CO;2-G 10.1016/j.ijrobp.2018.05.009 10.1002/ajh.23745 10.1111/bjh.13870 10.1111/j.1600-0609.2009.01251.x |
| ContentType | Journal Article |
| Copyright | 2019 Elsevier Inc. Copyright © 2019 Elsevier Inc. All rights reserved. Attribution - NonCommercial |
| Copyright_xml | – notice: 2019 Elsevier Inc. – notice: Copyright © 2019 Elsevier Inc. All rights reserved. – notice: Attribution - NonCommercial |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 1XC VOOES |
| DOI | 10.1016/j.ijrobp.2019.10.043 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1879-355X |
| EndPage | 596 |
| ExternalDocumentID | oai_HAL_hal_03227875v1 31707123 10_1016_j_ijrobp_2019_10_043 S0360301619339677 |
| Genre | Journal Article |
| GroupedDBID | --- --K .1- .FO 0R~ 1B1 1P~ 1RT 1~5 4.4 457 4G. 53G 5RE 7-5 AAEDT AAEDW AALRI AAWTL AAXUO ABJNI ABLJU ABNEU ABOCM ABUDA ACGFS ACIUM ACVFH ADBBV ADCNI ADVLN AENEX AEUPX AEVXI AFPUW AFRHN AFTJW AGCQF AHHHB AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ BELOY DU5 EBS EFKBS F5P FDB GBLVA HED HMO IHE J1W KOM LX3 M41 MO0 O9- OC~ OO- RNS ROL RPZ SDG SEL SES SSZ UV1 XH2 Z5R ~S- AAIAV AFCTW AGZHU ALXNB EFJIC ZA5 .55 .GJ 29J 5VS AAQFI AAQQT AAQXK AAYWO AAYXX ABEFU ABWVN ACRPL ADMUD ADNMO AFFNX AFJKZ AGQPQ AGRDE ASPBG AVWKF AZFZN CITATION EJD FEDTE FGOYB FIRID G-2 HMK HVGLF HX~ HZ~ NQ- R2- SAE SEW UDS X7M XPP ZGI CGR CUY CVF ECM EIF NPM 7X8 1XC VOOES |
| ID | FETCH-LOGICAL-c449t-3fb1f2f406070698fed1916e90a9306d1808344c1b4819fc2668ad822b218f0b3 |
| ISSN | 0360-3016 1879-355X |
| IngestDate | Fri Sep 12 12:50:14 EDT 2025 Sun Sep 28 12:04:11 EDT 2025 Wed Feb 19 02:31:24 EST 2025 Wed Oct 01 01:53:52 EDT 2025 Thu Apr 24 22:55:26 EDT 2025 Fri Feb 23 02:49:35 EST 2024 Tue Aug 26 16:45:25 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | Copyright © 2019 Elsevier Inc. All rights reserved. Attribution - NonCommercial: http://creativecommons.org/licenses/by-nc |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c449t-3fb1f2f406070698fed1916e90a9306d1808344c1b4819fc2668ad822b218f0b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-1795-7509 0000-0002-3527-4082 |
| OpenAccessLink | https://hal.science/hal-03227875 |
| PMID | 31707123 |
| PQID | 2313652093 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | hal_primary_oai_HAL_hal_03227875v1 proquest_miscellaneous_2313652093 pubmed_primary_31707123 crossref_citationtrail_10_1016_j_ijrobp_2019_10_043 crossref_primary_10_1016_j_ijrobp_2019_10_043 elsevier_sciencedirect_doi_10_1016_j_ijrobp_2019_10_043 elsevier_clinicalkey_doi_10_1016_j_ijrobp_2019_10_043 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-03-01 |
| PublicationDateYYYYMMDD | 2020-03-01 |
| PublicationDate_xml | – month: 03 year: 2020 text: 2020-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | International journal of radiation oncology, biology, physics |
| PublicationTitleAlternate | Int J Radiat Oncol Biol Phys |
| PublicationYear | 2020 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Mheidly, Lamy, Escoffre (bib17) 2016; 128 Avilés, Huerta-Guzmán, Delgado, Fernández, Díaz-Maqueo (bib11) 1996; 14 Benboubker, Dimopoulos, Dispenzieri (bib18) 2014; 371 Thumallapally, Meshref, Mousa, Terjanian (bib4) 2017; 17 Sasaki, Yasuda, Abe (bib6) 2012; 82 Tsang, Gospodarowicz, Pintilie (bib7) 2001; 50 Rajkumar, Dimopoulos, Palumbo (bib1) 2014; 15 Reed, Shah, Medeiros (bib5) 2011; 117 Ozsahin, Tsang, Poortmans (bib3) 2006; 64 Caers, Paiva, Zamagni (bib19) 2018; 11 Hill, Rawstron, de Tute, Owen (bib12) 2014; 124 Guo, Zhang, Wang (bib21) 2013; 6 de Waal, Leene, Veeger (bib14) 2016; 175 Chargari, Kirova, Zefkili (bib25) 2009; 83 Frassica, Frassica, Schray, Sim, Kyle (bib20) 1989; 16 Le Ray, Belin, Plancher (bib15) 2018; 159 Dores, Landgren, McGlynn (bib2) 2009; 144 Finsinger, Grammatico, Chisini (bib22) 2016; 172 Zhu, Zou, You (bib8) 2016; 16 Chargari, Hijal, Bouscary (bib24) 2012; 37 Knobel, Zouhair, Tsang (bib9) 2006; 6 Sharpley, Neffa, Panitsas (bib23) 2019; 14 Tsang, Campbell, Goda (bib10) 2018; 101 Katodritou, Terpos, Symeonidis (bib13) 2014; 89 Wiazzane, Chargari, Plancher (bib16) 2013; 5 Thumallapally (10.1016/j.ijrobp.2019.10.043_bib4) 2017; 17 Chargari (10.1016/j.ijrobp.2019.10.043_bib24) 2012; 37 Reed (10.1016/j.ijrobp.2019.10.043_bib5) 2011; 117 Ozsahin (10.1016/j.ijrobp.2019.10.043_bib3) 2006; 64 Le Ray (10.1016/j.ijrobp.2019.10.043_bib15) 2018; 159 Katodritou (10.1016/j.ijrobp.2019.10.043_bib13) 2014; 89 Knobel (10.1016/j.ijrobp.2019.10.043_bib9) 2006; 6 Wiazzane (10.1016/j.ijrobp.2019.10.043_bib16) 2013; 5 Rajkumar (10.1016/j.ijrobp.2019.10.043_bib1) 2014; 15 Dores (10.1016/j.ijrobp.2019.10.043_bib2) 2009; 144 Guo (10.1016/j.ijrobp.2019.10.043_bib21) 2013; 6 Sharpley (10.1016/j.ijrobp.2019.10.043_bib23) 2019; 14 Avilés (10.1016/j.ijrobp.2019.10.043_bib11) 1996; 14 Tsang (10.1016/j.ijrobp.2019.10.043_bib10) 2018; 101 Caers (10.1016/j.ijrobp.2019.10.043_bib19) 2018; 11 Zhu (10.1016/j.ijrobp.2019.10.043_bib8) 2016; 16 Benboubker (10.1016/j.ijrobp.2019.10.043_bib18) 2014; 371 Finsinger (10.1016/j.ijrobp.2019.10.043_bib22) 2016; 172 Frassica (10.1016/j.ijrobp.2019.10.043_bib20) 1989; 16 Mheidly (10.1016/j.ijrobp.2019.10.043_bib17) 2016; 128 Tsang (10.1016/j.ijrobp.2019.10.043_bib7) 2001; 50 Sasaki (10.1016/j.ijrobp.2019.10.043_bib6) 2012; 82 Hill (10.1016/j.ijrobp.2019.10.043_bib12) 2014; 124 Chargari (10.1016/j.ijrobp.2019.10.043_bib25) 2009; 83 de Waal (10.1016/j.ijrobp.2019.10.043_bib14) 2016; 175 |
| References_xml | – volume: 64 start-page: 210 year: 2006 end-page: 217 ident: bib3 article-title: Outcomes and patterns of failure in solitary plasmacytoma: A multicenter Rare Cancer Network study of 258 patients publication-title: Int J Radiat Oncol Biol Phys – volume: 6 start-page: 1659 year: 2013 end-page: 1666 ident: bib21 article-title: Prognostic factors associated with solitary plasmacytoma publication-title: Onco Targets Ther – volume: 159 start-page: 1756 year: 2018 end-page: 1758 ident: bib15 article-title: Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapy publication-title: Leuk Lymphoma – volume: 117 start-page: 4468 year: 2011 end-page: 4674 ident: bib5 article-title: Solitary plasmacytomas: Outcome and prognostic factors after definitive radiation therapy publication-title: Cancer – volume: 11 start-page: 10 year: 2018 ident: bib19 article-title: Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European expert panel publication-title: J Hematol Oncol – volume: 15 start-page: e538 year: 2014 end-page: e548 ident: bib1 article-title: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma publication-title: Lancet Oncol – volume: 16 start-page: 777 year: 2016 ident: bib8 article-title: Establishment of an innovative staging system for extramedullary plasmacytoma publication-title: BMC Cancer – volume: 128 year: 2016 ident: bib17 article-title: Adjuvant chemotherapy in the treatment of solitary bone plasmacytoma publication-title: Blood – volume: 50 start-page: 113 year: 2001 end-page: 120 ident: bib7 article-title: Solitary plasmacytoma treated with radiotherapy: Impact of tumor size on outcome publication-title: Int J Radiat Oncol Biol Phys – volume: 89 start-page: 803 year: 2014 end-page: 808 ident: bib13 article-title: Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients publication-title: Am J Hematol – volume: 16 start-page: 43 year: 1989 end-page: 48 ident: bib20 article-title: Solitary plasmacytoma of bone: Mayo Clinic experience publication-title: Int J Radiat Oncol Biol Phys – volume: 83 start-page: 66 year: 2009 end-page: 71 ident: bib25 article-title: Solitary plasmocytoma: Improvement in critical organs sparing by means of helical tomotherapy publication-title: Eur J Haematol – volume: 101 start-page: 794 year: 2018 end-page: 808 ident: bib10 article-title: Radiation therapy for solitary plasmacytoma and multiple myeloma: Guidelines from the International Lymphoma Radiation Oncology Group publication-title: Int J Radiat Oncol Biol Phys – volume: 14 start-page: e0219857 year: 2019 ident: bib23 article-title: Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era publication-title: PLoS ONE – volume: 124 start-page: 1296 year: 2014 end-page: 1299 ident: bib12 article-title: Outcome prediction in plasmacytoma of bone: A risk model utilizing bone marrow flow cytometry and light-chain analysis publication-title: Blood – volume: 371 start-page: 906 year: 2014 end-page: 917 ident: bib18 article-title: Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma publication-title: N Engl J Med – volume: 172 start-page: 554 year: 2016 end-page: 560 ident: bib22 article-title: Clinical features and prognostic factors in solitary plasmacytoma publication-title: Br J Haematol – volume: 82 start-page: 626 year: 2012 end-page: 634 ident: bib6 article-title: Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy publication-title: Int J Radiat Oncol Biol Phys – volume: 6 start-page: 118 year: 2006 ident: bib9 article-title: Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study publication-title: BMC Cancer – volume: 175 start-page: 661 year: 2016 end-page: 667 ident: bib14 article-title: Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands publication-title: Br J Hematol – volume: 37 start-page: 26 year: 2012 end-page: 30 ident: bib24 article-title: The role of helical tomotherapy in the treatment of bone plasmacytoma publication-title: Med Dosim – volume: 17 start-page: 13 year: 2017 ident: bib4 article-title: Solitary plasmacytoma: Population-based analysis of survival trends and effect of various treatment modalities in the USA publication-title: BMC Cancer – volume: 14 start-page: 111 year: 1996 end-page: 117 ident: bib11 article-title: Improved outcome in solitary bone plasmacytomata with combined therapy publication-title: Hematol Oncol – volume: 144 start-page: 86 year: 2009 end-page: 94 ident: bib2 article-title: Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: Incidence and survival in the United States, 1992-2004 publication-title: Br J Haematol – volume: 5 start-page: 248 year: 2013 end-page: 252 ident: bib16 article-title: Helical tomotherapy and systemic targeted therapies in solitary plasmacytoma: Pilot study publication-title: World J Radiol – volume: 64 start-page: 210 year: 2006 ident: 10.1016/j.ijrobp.2019.10.043_bib3 article-title: Outcomes and patterns of failure in solitary plasmacytoma: A multicenter Rare Cancer Network study of 258 patients publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2005.06.039 – volume: 50 start-page: 113 year: 2001 ident: 10.1016/j.ijrobp.2019.10.043_bib7 article-title: Solitary plasmacytoma treated with radiotherapy: Impact of tumor size on outcome publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(00)01572-8 – volume: 117 start-page: 4468 year: 2011 ident: 10.1016/j.ijrobp.2019.10.043_bib5 article-title: Solitary plasmacytomas: Outcome and prognostic factors after definitive radiation therapy publication-title: Cancer doi: 10.1002/cncr.26031 – volume: 159 start-page: 1756 year: 2018 ident: 10.1016/j.ijrobp.2019.10.043_bib15 article-title: Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapy publication-title: Leuk Lymphoma doi: 10.1080/10428194.2017.1393667 – volume: 14 start-page: e0219857 year: 2019 ident: 10.1016/j.ijrobp.2019.10.043_bib23 article-title: Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era publication-title: PLoS ONE doi: 10.1371/journal.pone.0219857 – volume: 16 start-page: 777 year: 2016 ident: 10.1016/j.ijrobp.2019.10.043_bib8 article-title: Establishment of an innovative staging system for extramedullary plasmacytoma publication-title: BMC Cancer doi: 10.1186/s12885-016-2824-x – volume: 82 start-page: 626 year: 2012 ident: 10.1016/j.ijrobp.2019.10.043_bib6 article-title: Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2010.11.037 – volume: 144 start-page: 86 year: 2009 ident: 10.1016/j.ijrobp.2019.10.043_bib2 article-title: Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: Incidence and survival in the United States, 1992-2004 publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2008.07421.x – volume: 17 start-page: 13 year: 2017 ident: 10.1016/j.ijrobp.2019.10.043_bib4 article-title: Solitary plasmacytoma: Population-based analysis of survival trends and effect of various treatment modalities in the USA publication-title: BMC Cancer doi: 10.1186/s12885-016-3015-5 – volume: 6 start-page: 118 year: 2006 ident: 10.1016/j.ijrobp.2019.10.043_bib9 article-title: Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study publication-title: BMC Cancer doi: 10.1186/1471-2407-6-118 – volume: 124 start-page: 1296 year: 2014 ident: 10.1016/j.ijrobp.2019.10.043_bib12 article-title: Outcome prediction in plasmacytoma of bone: A risk model utilizing bone marrow flow cytometry and light-chain analysis publication-title: Blood doi: 10.1182/blood-2014-04-566521 – volume: 15 start-page: e538 year: 2014 ident: 10.1016/j.ijrobp.2019.10.043_bib1 article-title: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70442-5 – volume: 128 year: 2016 ident: 10.1016/j.ijrobp.2019.10.043_bib17 article-title: Adjuvant chemotherapy in the treatment of solitary bone plasmacytoma publication-title: Blood doi: 10.1182/blood.V128.22.4514.4514 – volume: 371 start-page: 906 year: 2014 ident: 10.1016/j.ijrobp.2019.10.043_bib18 article-title: Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma publication-title: N Engl J Med doi: 10.1056/NEJMoa1402551 – volume: 16 start-page: 43 year: 1989 ident: 10.1016/j.ijrobp.2019.10.043_bib20 article-title: Solitary plasmacytoma of bone: Mayo Clinic experience publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/0360-3016(89)90008-4 – volume: 37 start-page: 26 year: 2012 ident: 10.1016/j.ijrobp.2019.10.043_bib24 article-title: The role of helical tomotherapy in the treatment of bone plasmacytoma publication-title: Med Dosim doi: 10.1016/j.meddos.2010.12.009 – volume: 6 start-page: 1659 year: 2013 ident: 10.1016/j.ijrobp.2019.10.043_bib21 article-title: Prognostic factors associated with solitary plasmacytoma publication-title: Onco Targets Ther – volume: 5 start-page: 248 year: 2013 ident: 10.1016/j.ijrobp.2019.10.043_bib16 article-title: Helical tomotherapy and systemic targeted therapies in solitary plasmacytoma: Pilot study publication-title: World J Radiol doi: 10.4329/wjr.v5.i6.248 – volume: 175 start-page: 661 year: 2016 ident: 10.1016/j.ijrobp.2019.10.043_bib14 article-title: Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands publication-title: Br J Hematol doi: 10.1111/bjh.14291 – volume: 11 start-page: 10 year: 2018 ident: 10.1016/j.ijrobp.2019.10.043_bib19 article-title: Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European expert panel publication-title: J Hematol Oncol doi: 10.1186/s13045-017-0549-1 – volume: 14 start-page: 111 year: 1996 ident: 10.1016/j.ijrobp.2019.10.043_bib11 article-title: Improved outcome in solitary bone plasmacytomata with combined therapy publication-title: Hematol Oncol doi: 10.1002/(SICI)1099-1069(199609)14:3<111::AID-HON575>3.0.CO;2-G – volume: 101 start-page: 794 year: 2018 ident: 10.1016/j.ijrobp.2019.10.043_bib10 article-title: Radiation therapy for solitary plasmacytoma and multiple myeloma: Guidelines from the International Lymphoma Radiation Oncology Group publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2018.05.009 – volume: 89 start-page: 803 year: 2014 ident: 10.1016/j.ijrobp.2019.10.043_bib13 article-title: Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients publication-title: Am J Hematol doi: 10.1002/ajh.23745 – volume: 172 start-page: 554 year: 2016 ident: 10.1016/j.ijrobp.2019.10.043_bib22 article-title: Clinical features and prognostic factors in solitary plasmacytoma publication-title: Br J Haematol doi: 10.1111/bjh.13870 – volume: 83 start-page: 66 year: 2009 ident: 10.1016/j.ijrobp.2019.10.043_bib25 article-title: Solitary plasmocytoma: Improvement in critical organs sparing by means of helical tomotherapy publication-title: Eur J Haematol doi: 10.1111/j.1600-0609.2009.01251.x |
| SSID | ssj0001174 |
| Score | 2.4342828 |
| Snippet | The study evaluates the results of the concurrent use of lenalidomide-dexamethasone with intensity modulated radiation therapy (IMRT) for solitary plasmacytoma... Purpose: The study evaluates the results of the concurrent use of lenalidomide-dexamethasone with intensity modulated radiation therapy (IMRT) for solitary... |
| SourceID | hal proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 589 |
| SubjectTerms | Adult Aged Antineoplastic Agents - therapeutic use Cancer Chemoradiotherapy - adverse effects Chemoradiotherapy - methods Dexamethasone - therapeutic use Disease-Free Survival Drug Therapy, Combination Female Humans Lenalidomide - therapeutic use Life Sciences Male Middle Aged Multiple Myeloma Plasmacytoma - mortality Plasmacytoma - therapy Progression-Free Survival Radiotherapy, Intensity-Modulated - adverse effects Survival Rate |
| Title | Solitary Plasmacytoma Treated by Lenalidomide-Dexamethasone in Combination with Radiation Therapy: Clinical Outcomes |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0360301619339677 https://dx.doi.org/10.1016/j.ijrobp.2019.10.043 https://www.ncbi.nlm.nih.gov/pubmed/31707123 https://www.proquest.com/docview/2313652093 https://hal.science/hal-03227875 |
| Volume | 106 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1879-355X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001174 issn: 0360-3016 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1879-355X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001174 issn: 0360-3016 databaseCode: AKRWK dateStart: 19761001 isFulltext: true providerName: Library Specific Holdings |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa6TkK8IO6UmwziDaVK6lx5qwZTxVZAawd9i2LHGa1ogroUMf4uf4Rz4kszRrWxl6i1atfJ-ZLzHec7x4S84sJlSZwLiE1y6fhs4DkZj1xHhElYeFkoAoGB4vhDODr238-CWafzu6VaWte8L379M6_kOlaFNrArZsn-h2XtoNAAn8G-cAQLw_FKNp6geA1lb5-AAy8zcVZXy-z1FHmgIpaHEnl2Xi3ncIneyp8ZbhidAcWWKttvCXGxQkCzHnuEhQqar1NVbADXC_ZM7uTHdQ0noTWHi40CfrOg2CpDsbJDVaWwGTF8kxyjllQsox_PT8qqcQj7GZ9v8tMmCCorQhuWddUSAgxXp82L_riUjs220Ck7G1HvZxy61IlJJ2swjBY36cUOiGyt2kutwJksnHMiUXDC4EtcT5fUVg_yOEoc4FKzc096N2xBmrWe24Hax0hTgEBtsnvBu6iFjkV_vlhVHIudekkfpYGq0NRfdbsnOC2cFVBkloRRtEN2B1EYDrpkd3hw9OXAEgZPFws3p2EyPBsZ4sX_2sagdr6ilHdbnNTwpeltcksHOnSoUHuHdGR5l9wYaynHPVIb8NI2eKkGL-VndDt46bykLfBSBC-14KUavG-ogS410L1PjvffTfdGjt4CxBG-n9QOK7hXDApgneCawiQuZO5BQCMTN0sg2M292MWNYoTHfaC2hQC6GWc5kF4O1LVwOXtAugAx-YhQYOJuJLCCoZf4POaxjLIgzhlQ4EJKJnuEmcuaCl0fH7dp-ZYaIeQiVcZI0RjYCsboEcf2-q7qw1zy-8BYLDW5z-CtU4DYJf0i209zY8V5r9DzJQDDTg7LyY-Ghym2uQwT4aPgh9cjLwxuUvAv-NIwK2W1Pk0h_mMhauVgoIcKUHYsiD0gQhmwx9ee3BNyc3ObPyXderWWz4Dl1_y5vkv-AMMoAY8 |
| linkProvider | Library Specific Holdings |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Solitary+Plasmacytoma+Treated+by+Lenalidomide-Dexamethasone+in+Combination+with+Radiation+Therapy%3A+Clinical+Outcomes&rft.jtitle=International+journal+of+radiation+oncology%2C+biology%2C+physics&rft.au=Mignot%2C+Fabien&rft.au=Schernberg%2C+Antoine&rft.au=Ars%C3%A8ne-Henry%2C+Alexandre&rft.au=Vignon%2C+Marguerite&rft.date=2020-03-01&rft.pub=Elsevier+Inc&rft.issn=0360-3016&rft.eissn=1879-355X&rft.volume=106&rft.issue=3&rft.spage=589&rft.epage=596&rft_id=info:doi/10.1016%2Fj.ijrobp.2019.10.043&rft.externalDocID=S0360301619339677 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0360-3016&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0360-3016&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0360-3016&client=summon |